Cargando…
Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?
Autores principales: | Maguire, Cole, Frohman, Teresa, Zamvil, Scott S., Frohman, Elliot, Melamed, Esther |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309524/ https://www.ncbi.nlm.nih.gov/pubmed/32527763 http://dx.doi.org/10.1212/NXI.0000000000000811 |
Ejemplares similares
-
Mitigating alemtuzumab-associated autoimmunity in MS: A “whack-a-mole” B-cell depletion strategy
por: Meltzer, Ethan, et al.
Publicado: (2020) -
Part I. SARS-CoV-2 triggered ‘PANIC’ attack in severe COVID-19
por: Frohman, Elliot M., et al.
Publicado: (2020) -
Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology
por: Calabresi, Peter A., et al.
Publicado: (2010) -
Aquatic training in MS: neurotherapeutic impact upon quality of life
por: Frohman, Ashley N, et al.
Publicado: (2015) -
Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease()
por: Frohman, Elliot M., et al.
Publicado: (2021)